Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4638358 | 0.90 | PTGS2 (0.42) | PTGS2MEN1KMT2ATP53AGTR1 | |
| SCHEMBL806970 | 0.82 | GAA (0.47) | PTGS2KMT2ASOS1PTGDR2PSEN1 | |
| SCHEMBL13601374 | 0.82 | MAPK1 (0.48) | MEN1KMT2APTGDR2ALDH1A1 | |
| SCHEMBL585689 | 0.80 | PTGS2 (0.65) | PTGS2MEN1KMT2ATP53AGTR1 | |
| SCHEMBL9711269 | 0.79 | SOS1 (0.42) | PTGS2MEN1KMT2ATP53AGTR1 | |
| SCHEMBL7946206 | 0.78 | FLT1 (0.44) | PTGS2PTGDR2PTGS1FLT1FLT4 | |
| SCHEMBL7948250 | 0.78 | GAA (0.44) | PTGDR2ALDH1A1 | |
| SCHEMBL14837371 | 0.78 | TSHR (0.50) | PTGS2MEN1KMT2APTGS1TSHR | |
| SCHEMBL19447435 | 0.78 | PSEN1 (0.45) | MEN1KMT2APTGDR2TSHRPSEN1 | |
| SCHEMBL4618133 | 0.78 | SOS1 (0.54) | PTGS2MEN1KMT2ATP53AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| EP-1765768-B1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2013-11-06 | — | — | EP | disclosed |
| CN-101326161-B | Novel compounds | ASTRAZENECA AB | 2013-04-17 | — | — | CN | disclosed |
| EP-2346819-B1 | NAPHTHYLACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-8394986-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (GB) | 2013-03-12 | — | — | US | disclosed |
| CN-102557971-A | Substituted acids for the treatment of respiratory diseases | ASTRAZENECA AB | 2012-07-11 | — | — | CN | disclosed |
| CN-101014564-B | Substituted acids for the treatment of respiratory diseases | ASTRAZENECA AB | 2012-05-09 | — | — | CN | disclosed |
| EP-1963259-B1 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| CN-101014564-A | Substituted acids for the treatment of respiratory diseases | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | CN | disclosed |
| WO-2007068894-A2 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
| EP-1765768-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| EP-1756076-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| US-20060293352-A1 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| CN-1845894-A | phenoxyacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-10-11 | — | — | CN | disclosed |
| EP-1660431-A2 | PHENOXYACETIC ACID DERIVATIVES | Astrazeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006005909-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005018529-A2 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293352-A1 | Phenoxiacetic acid derivatives | HRH2, HRH1, HCAR2 | PTGS2 21/4885MEN1 3996/4885KMT2A 647/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | PTGS2 2677/4885MEN1 2716/4885KMT2A 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.